General information

After the molecular analysis of your tumor, it may happen that a molecular marker (e.g. driver mutation or marker of response to immunotherapy) is found, but that there is no approved treatment available for it currently. In this case, we try to provide you with a suitable clinical trial, where you will be treated with a new drug.
Netzwerk Genomische Medizin (NGM) Lungenkrebs

Here, 2 options are available: You will be treated within a trial by the Lung Cancer Study Group Cologne or within a trial by a partner of the Network Genomic Medicine.

Last update: 17. March 2016 , 8:47

Molecular diagnostics

As the first group in Europe, the Network Genomic Medicine has offered a comprehensive analysis of tumor material since 2012. By means of a multiplex-test in combination with highly sensitive deep sequencing even rare gene mutations in the smallest tissue samples are detected reliably

Second opinion

Do you have questions about your disease or your current therapy? Or maybe you would like to know if for you a personalized treatment approach or immunotherapy might be considered. Please feel free to contact us!

Clinical trials

At the Network Genomic Medicine we try to offer an appropriate clinical trial testing a new drug to all our patients who have a detected mutation, for which there has no drug been approved for treatment yet. For that we work closely together with the Lung Cancer Group Cologne.